Screening for Advanced Liver Fibrosis Using Non-invasive Tests in Primary Care
NCT ID: NCT06119997
Last Updated: 2025-04-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
500 participants
OBSERVATIONAL
2025-06-01
2027-07-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Given this opportunity to identify advanced fibrosis in asymptomatic patients, the project aims to set up this screening program in the Grenoble area with Biogroup Laboratories, in collaboration with the Hepato-gastroenterology department (HGE) of Grenoble University Hospital. The aim of this study is to evaluate the success of sequential screening using FIB-4, followed by a specialized fibrosis test for the diagnosis of advanced hepatic fibrosis
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
SCREaning of Advanced Liver Fibrosis Using Non-Invasive Tests in General Population
NCT05880173
Screening for Chronic Liver Diseases in General Population
NCT06366425
City-hospital Collaboration for the Early Screening of Hepatic Fibrosis in Primary Care: a Secondary Prevention Project in the Grenoble Health Basin
NCT07031089
Screening for Liver Fibrosis by Using Non-invasive Methods in Patients With Diabetes. A Prospective Study
NCT01306110
Validation in a Non-targeted Population of Single Ultrasound Doppler Signs of Liver Fibrosis
NCT03027921
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* FIB-4 2.67
* Patients covered by Health Insurance System
Exclusion Criteria
* Conditions associated with high risk false-positive FIB-4: ASAT or ALAT \> 300 IU/L, platelets \<50 G/L or \>500 G/L.
* Patient refusing to participate
* Subjects under guardianship or deprived of liberty
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Grenoble
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
38RC22.0266
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.